Dr. Haley Ellis discusses efficacy data from the TOPAZ-1 clinical trial, including new 4-year OS data showing prolonged survival benefit with durvalumab plus gemcitabine/cisplatin. She also covers key exploratory analysis data from the trial.
Dr. Midhun Malla discusses the evolving treatment landscape for advanced unresectable hepatocellular carcinoma (HCC), highlighting the positive outcomes of the Phase 3 HIMALAYA trial and the STRIDE regimen of tremelimumab and durvalumab. He emphasizes that real-world evidence increasingly supports these novel immune checkpoint inhibitor combinations, while noting that ongoing trials like Sierra and LIVER-R are essential for evaluating their safety and efficacy in broader, more complex patient populations.
©2026 Oncology Matrix. All Rights Reserved.
